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Renal failure after omeprazole
SIR,-An 86-year-old woman had a 10 year history of
oesophagitis and had been treated intermittently with cimetidine or
ranitidine. Because of progression in symptoms in 1989,
omeprazole 40 mg daily was started. At that time the patient had
normal serum creatinine concentration. 2 months later she was
admitted with renal failure: maximum serum creatinine 858 pmol/L
(normal < 120). A renal needle biopsy revealed interstitial
inflammation, with plasma cells, lymphocytes, and eosinophils and
patchy tubulitis but no effect on glomeruli, which is characteristic of
acute interstitial nephritis.1 2 weeks before admission the patient
had been treated with erythromycin for suspected pneumonia. Both
drugs were withdrawn, and the patient regained normal renal
function on treatment with diuretics. Erythromycin was suspected
of being the drug causing the renal failure.
In 1992, during cimetidine treatment, the patient had a peptic
stricture of the oesophagus and omeprazole was given with
surveillance of renal function. Within a week the patient developed
high temperature, a rash, eosinophilia, and diminishing renal
function. The patient did not receive any other drugs, and
omeprazole was withdrawn after 9 days. The renal failure
progressed to anuria, and necessitated haemodialysis for a week.
The renal function remained severely affected, and after 3 months
serum creatinine had declined from 810 to 396 mmol/L.
Our patient had typical acute interstitial nephritis, with the triad
of high temperature, rash, and eosinophilia.1 The pathophysiology
remains unclear, but cell-mediated immunity is probably important
in most cases The allergic nature of our patient’s disease is
favoured by the fact that she had previously reacted with rashes to
other drugs (amiloride with hydrochlorthiazide, phenylbutazone,
and penicillin), and in 1972 she had had sarcoidosis (verified by
mediastinal gland biopsy) that spontaneously subsided. Patients
with sarcoidosis react with an enhanced T-lymphocyte-mediated
immune response to various antigens.
This is the second case of acute interstitial nephritis due to
omeprazole, and the diagnosis was confirmed by renal biopsy. The
first case was a 74-year-old woman with oesophagitis who twice had
increased serum creatinine and eosinophilia/eosinophiluria for
weeks after treatment with omeprazole.3
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Adverse events after triazolam substitution
SIR,-It is just over a year since the UK licensing authorities
suspended the hypnotic triazolam.
To examine the effects of this regulatory decision on patients in
general practice, whose insomnia had been successfully treated with
triazolam, we retrospectively surveyed general practitioners who
had to switch their sleep-disturbed patients suddenly to another
hypnotic. 163 general practitioners reviewed 1193 patients’ records
(M/F 333/860, mean age 66-4) and completed a standardised
questionnaire and individual case-record form that measured global
clinical impression, daytime effects, tolerability, and preference for
medication.
In response to an opinion-poll question, mean ratings on a visual
analogue scale showed that the physicians questioned disagreed
with the suspension of triazolam, felt that their prescribing
flexibility had been compromised, and thought that the suspension
of triazolam had not benefited their patients.
Temazepam was the substitute prescribed to 806 (67-6%) of the
patients. Other substitute therapies were loprazolam (8-7%),
nitrazepam (7-3%), lonnetazepam (5-3%), chloral betaine (3-6%),
and zopiclone (3-6%). Various antidepressants (0-5%),
antipsychotics (0-2%), and anxiolytics (0-9%) were also used.
The number of adverse events reported for triazolam during the
three months before the suspension was compared with that during
the first three months of substitute therapy, as an index of the
relative safety of triazolam. 284 (23-8%) patients reported side-
effects while using triazolam compared with 378 (31-7%) with
substitute therapy. The central nervous system (CNS) events
reported with specific treatments (lormetazepam, 22%;
nitrazepam, 21%; zopiclone, 19%; temazepam, 18%; chloral
betaine, 18%; and loprazolam, 12%) were in excess of those
reported with triazolam (9%). The most frequent reports with
triazolam were insomnia and memory problems, both at 0-4%,
whereas for the substitutes as a group, insomnia affected 7-0%,
daytime drowsiness 1-3%, and anxiety 1-1%. For the most
frequently prescribed substitute, temazepam, the most common
CNS events related to treatment were insomnia 7-1%, daytime
drowsiness 1 -1 %, and anxiety 1-2%.
These results must be viewed within the context of the limitations
of a retrospective survey of patients with some tolerance of
triazolam. Furthermore, we did not control for different regimens.
However, the number of general practitioners surveyed would
effectively reduce any systematic bias and, in the light of the
media-driven commentary on triazolam, the reporting of CNS
events with triazolam would be expected to be over-reported. Also,
if any substitute therapy was perceived to be as effective and as safe
as triazolam, this finding could easily have been reflected in our
survey.
If the rationale for the suspension of triazolam was to ensure the
safety of patients using hypnotics, the UK regulators’ decision was
faulty. None of the substitute therapies had a profile of CNS
side-effects superior to that of triazolam. Indeed, most substitutes
were associated in physicians’ reports with noticeably more CNS
side-effects--especially those likely to interfere with the daily
wellbeing and safety of patients.
Human Psychopharmacology Research Unit,
University of Surrey,
Milford Hospital,





SIR,-Dr Bradley (Oct 3, p 848) reiterates the once-popular
notion that human obesity is caused by excessive consumption of
sugar-containing and therefore palatable foods. His argument is
based on the faulty premise that obesity was uncommon in
traditional societies whose "bland and monotonous" diets provided
an average of 50% of their energy from fat. On the contrary, most
pre-industrial diets provided a very small portion of energy from fat.
Subsistence-level farming chiefly involves tubers and starchy
roots/ Field agriculture has allowed the cultivation of grasses such
as maize, oats, barley, and sorghum, including such major food
grains as rice and wheat.  Geographic location also plays a part.
Thus manioc is still the basic foodstuff of African countries, maize is
the staple food of Central and South America, whereas the Asian
diet is based on rice. Most so-called traditional diets are very high in
complex carbohydrates, but very low in fats and oils. Until recently,
the Japanese diet provided less than 10% of daily energy from fat.2
The few contrary examples of the cattle-rearing Masai of East
Africa or the hunting and fishing Arctic Eskimos have long been
known to anthropologists and nutritionists. Although these groups
incorporate meat and fish into their diets, and so run counter to the
norm, their fat intake is surprisingly low compared with that of
many western societies.
Although animal fats were the most sought-after item in
pre-industrial diets, their consumption was rare, and was often
associated with feasts and ritual sharing.3 It was economic
prosperity that brought about increased meat consumption and the
selective breeding of animals for the maximum fat content. The
French sociologist Claude Fischler4 notes that historians have long
indexed the prosperity of an era, or the membership in a given social
class, in terms of per caput meat consumption. Prosperity is
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associated with increased consumption of animal fats and a decline
in the consumption of grain products.
Bradley mistakenly equates palatability exclusively with the
sweet taste of sugar. In reality, fats have a more decisive role in
determining the palatability of the diet.5,6 Fats endow foods with
various flavours, aromas, and textures, and some of the most
palatable foods in the human diet are those that are rich in fat.
Taste-preference studies have shown that obese women gave
highest preference ratings to stimuli that were low in sugar but were
rich in fat.7 Preferences for dietary sources of fat may in fact be a
shared feature of human obesity syndromes. Whereas obese men
typically listed meat dishes among their favourite foods, women
were more likely to express preferences for sweet, fat-rich desserts.8
Prosperity is, admittedly, also associated with increased sugar
consumption, because sucrose and fructose replace dietary starches
and grains .5 However, although the typical American diet provides
about 11 % of energy from added sugars, 38% of the energy comes
from fat, and, according to present medical consensus, fat is the
most important dietary factor in the aetiology of obesity.
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Genetic susceptibility to multiple sclerosis
linked to myelin basic protein gene
SIR,-Dr Tienari and colleagues’ report (Oct 24, p 987)
implicates the myelin basic protein (MBP) gene or an associated
gene in multiple sclerosis in high risk Finnish families. However,
although their criteria for multiple sclerosis are clear, those for optic
neuritis are not defined. Were these criteria clinical or based on
laboratory tests, or both? In the three pedigrees shown there were 82
individuals of whom 53 had optic neuritis or multiple sclerosis. Yet
there were 20 forebears in these pedigrees without any
demyelinating disease. Surely this is remarkable for a genetic
condition? It may be that in some, particularly pedigree 2 in which
five generations were shown and would cover at least 100 years, the
diagnosis was not made because the neurological conditions were
not recognised--or were they truly absent? The ratio of optic
neuritis to multiple sclerosis was about 3/2. Genetic studies of this
kind should be done in parallel in more than one country to compare
the patterns in different areas.
Although MBP sensitisation in rats and guineapigs induces
experimental allergic encephalitis, this is not associated with
demyelination, which is an essential pathological feature of multiple
sclerosis. In the guineapig, environmental features such as
pretreatment with a bacterial cell-wall component and non-
encephalitogenic proteinsl-3 can predispose to demyelination. This
finding suggests that demyelination is of multifactorial origin and
that environmental factors may include bacteria, viruses, or
components of microbial origin. In shiverer mice, in which the
MBP gene is known to be defective, the illness is present from birth
and affects all individuals, unlike multiple sclerosis. Apart from
MBP, the possible role of other myelin proteins4 and their genes and
associated genes also require investigation for alleleic variations.
Two factors that may contribute to demyelination are loss of
tolerance to a myelin protein and damage to a surveillance system
that prevents demyelination. The latter factor may be of genetic
origin and families prone to multiple sclerosis may be more
vulnerable than normal, according to this theory.5
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Authors’ reply
SIR,-Dr Colover’s comment about the high frequency of optic
neuritis in multiple sclerosis families was based on a mistake, which
had escaped our notice. Unfortunately, the symbol for optic neuritis
in fig 2 was wrongly assigned in the legend of the figure. The correct
symbol for males with optic neuritis should be a half-filled square
instead of an open square, which indicated unaffected males. The
number of subjects with this condition in the pedigrees shown in fig
2 is therefore only 1, instead of 53. The diagnostic criteria for optic
neuritis were both clinical and laboratory investigations: the
patients had had one attack of monosymptomatic disease without
any abnormal laboratory findings.
Colover questions the cause of demyelination in multiple
sclerosis, which remains unknown and is probably multifactorial
and therefore open to speculation. We regarded the following points
as relevant to our report. First, MBP is a target autoantigen in
experimental allergic encephalomyelitis of rodents and the analogy
with multiple sclerosis is unclear. Second, molecular mimicry
between MBP and viral proteins has been shown to be
pathologically important in an animal disease model. Third, two
mutations of MBP gene have been characterised in mice with
shiverer phenotype (a demyelinating disease); it is relevant to
address the known mutations of the MBP gene, although the disease
caused by these mutations is distinct from multiple sclerosis.
Finally, by finding linkage to MBP gene we can locate a genomic
variation conferring susceptibility to multiple sclerosis close to
MBP gene. However, linkage does not implicate MBP gene as the
defective gene, although it is a candidate gene: therefore our
conclusion remains that a polymorphism in the MBP gene or in
close vicinity has a role in the aetiopathogenesis of multiple sclerosis.
The role of other myelin genes is highly speculative since dozens
of other candidate genes could be implicated (eg, genes coding for
components of the immune system). Among myelin genes the
proteolipid protein gene is an unlikely candidate since it is located on
the X chromosome and no evidence for X-chromosomal
inheritance exists in multiple sclerosis. However, there are very few
experimental data for these other myelin genes.
Many theories of demyelination mechanisms accord with MBP
linkage, and the "damage to a surveillance system that prevents
demyelination" suggested by Colover is appealing. Accordingly,
demyelination in multiple sclerosis may well be secondary to
reduced remyelination capacity. In view of our finding and with
MBP as a candidate gene, this hypothesis could be explained by
several genetically determined factors: low levels of MBP
expression in multiple sclerosis patients; differences in MBP
isoforms (ie, reduced amount of those isoforms, which are produced
during active remyelination); and aminoacid variation in MBP
leading to a functionally defective protein. However, we feel that the
speculations regarding these mechanisms are, at this stage,
premature.
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